Orbis Health Solutions, LLC
Records under this name other than the patents Orbis Health Solutions, LLC holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 8 patents it holds.
Back to Orbis Health Solutions, LLC
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 10,675,249 | Vaccine delivery systems using yeast cell wall particles Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,179,343 | Vaccine delivery systems using yeast cell wall particles Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,759,429 | Vaccine delivery systems using yeast cell wall particles Formerly held In force · USPTO record | In force | USPTO record | |
| US 10,166,195 | Vaccine delivery systems using yeast cell wall particles Formerly held In force · USPTO record | In force | USPTO record | |
| US 11,826,476 | Vaccine delivery systems using yeast cell wall particles Formerly held In force · USPTO record | In force | USPTO record | |
| US 12,453,768 | Vaccines for in vivo expression of nucleic acids and methods of using the same Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,550,426 | Acetylated therapeutic procytotoxins Term ended Term ended May 16, 2026 · USPTO record | Term ended | Term ended May 16, 2026 | USPTO record |
| US 7,582,726 | VEGF receptor antagonists Term ended Term ended Jan 17, 2025 · USPTO record | Term ended | Term ended Jan 17, 2025 | USPTO record |
| US 10,801,041 | T7 alpha viral vector system Lapsed on the fee record Ended Oct 13, 2024 · USPTO record | Lapsed on the fee record | Ended Oct 13, 2024 | USPTO record |
| US 7,456,146 | Lytic peptide prodrugs Term ended Term ended Mar 11, 2024 · USPTO record | Term ended | Term ended Mar 11, 2024 | USPTO record |